Product Description
Avotermin, the first agent identified in this class, is the clinical application of human recombinant transforming growth factor beta3 (TGFbeta3), a key protein involved in scar-free healing observed in embryos. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18757391/)
Mechanisms of Action: TGFR Inhibitor
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Topical,Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Renovo
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Vision, Low|Depressive Disorder
Phase 2: Healthy Volunteers|Injuries/wounds Unspecified|Keloid|Varicose Veins|Burns Unspecified|Vision, Low|Nevus
Phase 1: Healthy Volunteers|Lymphoma|Injuries/wounds Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
KOHDIAK | P1 |
Not yet recruiting |
Lymphoma |
2021-02-01 |
|
Juvista in the prevention or reduction of the resultant scar following scar revision surgery. | P2 |
Completed |
Vision, Low|Burns Unspecified |
2011-03-03 |
|
Juvista in scar revision surgery of disfiguring scars | P3 |
Completed |
Vision, Low |
2011-01-30 |
|
Revise | P3 |
Completed |
Vision, Low|Depressive Disorder |
2011-01-01 |